Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29246 | 0.75 | — | — | |
| SCHEMBL416847 | 0.71 | TSHR (0.31) | TSHR | |
| SCHEMBL8492495 | 0.65 | — | — | |
| SCHEMBL917202 | 0.64 | MAOA (0.34) | — | |
| SCHEMBL4955366 | 0.62 | CA1 (0.34) | TSHR | |
| SCHEMBL15154 | 0.62 | TSHR (0.31) | TSHR | |
| SCHEMBL15466839 | 0.60 | CA1 (0.37) | — | |
| SCHEMBL1848730 | 0.60 | — | — | |
| SCHEMBL876180 | 0.60 | TSHR (0.33) | TSHR | |
| SCHEMBL4350203 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803129-B2 | CONTAINING MODIFIED COUMARIN COMPOUNDS; STABILITY, BRIGHTNESS, PURITY | RITDISPLAY CORPORATION (TW) | 2004-10-12 | — | — | US | claimed |
| US-6399756-B1 | OLIGONUCLEOTIDE | ISIS PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | claimed |
| US-6326478-B1 | OLIGONUCLEOTIDES AND MEDICAL DIAGNOSIS, METABOLISM | ISIS PHARMACEUTICALS, INC. | 2001-12-04 | — | — | US | claimed |
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-20140113093-A1 | Polymers with reduced estrogenic activity | SOLVAY SPECIALITY POLYMERS USA, LLC (US) | 2014-04-24 | — | — | US | disclosed |
| WO-2012160172-A1 | POLYMERS WITH REDUCED ESTROGENIC ACTIVITY | SOLVAY SPECIALTY POLYMERS USA, LLC (US) | 2012-11-29 | — | — | WO | disclosed |
| US-8288077-B2 | Chemically amplified resist composition and salt employed therein | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8268842-B2 | Fused ring 4-oxopyrimidine derivative | MSD K.K. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20110020749-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND SALT EMPLOYED THEREIN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-27 | — | — | US | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20090048295-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF | JANSSEN PHARMACEUTICE N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-6803129-B2 | CONTAINING MODIFIED COUMARIN COMPOUNDS; STABILITY, BRIGHTNESS, PURITY | RITDISPLAY CORPORATION (TW) | 2004-10-12 | — | — | US | disclosed |
| CN-1213382-A | Catalyst system and components | EXXON CHEMICAL PATENTS INC (US) | 1999-04-07 | — | — | CN | disclosed |
| EP-0880549-A2 | CATALYST SYSTEM AND COMPONENTS | EXXON CHEMICAL PATENTS INC. (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997030096-A2 | CATALYST SYSTEM AND COMPONENTS | EXXON CHEMICAL PATENTS INC. (US) | 1997-08-21 | — | — | WO | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048295-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF | C3AR1, C5AR1, C5AR2 | TSHR 2164/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | TSHR 227/4885 |
| US-20110020749-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND SALT EMPLOYED THEREIN | RER1, RARA, RARG | TSHR 1355/4885 |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | TSHR 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.